Literature DB >> 1332255

Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor.

C C Silliman1, G W Thurman, D R Ambruso.   

Abstract

Neutrophils (PMNs) initiate production of toxic oxygen metabolites through stimulation of an NADPH oxidase resulting in the reduction of oxygen to superoxide anion (O2-). The activity of this enzyme system may be primed by a variety of compounds. This laboratory investigated the possibility that stored blood components may contain agents which prime the PMN oxidase. At the time of outdate, packed red blood cells, whole blood, and platelet concentrates contained a priming agent which enhanced the PMN NADPH oxidase activity in response to a soluble stimulus, formyl-Met-Leu-Phe, by 2.1- to 2.8-fold. The priming activity was almost completely inhibited by WEB 2170, a specific platelet activating factor antagonist. Fresh plasma or fresh-frozen plasma did not exhibit priming activity. These data suggest that platelet-activating factor-like compounds are generated during the storage of cellular blood components. The presence of these agents in stored blood may suggest a role for specific compounds which prime PMNs and possibly mediate other effects which result in severe complications of transfusion therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332255     DOI: 10.1111/j.1423-0410.1992.tb02500.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  18 in total

Review 1.  Therapeutic options for transfusion related acute lung injury; the potential of the G2A receptor.

Authors:  Michael A Ellison; Daniel R Ambruso; Christopher C Silliman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  The mystery of transfusion-related acute lung injury.

Authors:  Neil Blumberg; Patricia J Sime; Richard P Phipps
Journal:  Transfusion       Date:  2011-10       Impact factor: 3.157

3.  Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice.

Authors:  Carlton C Barnett; Adam W Beck; Shane E Holloway; Marguerite Kehler; Marie K Schluterman; Rolf A Brekken; Jason B Fleming; Christopher C Silliman
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

Review 4.  Experimental models of transfusion-related acute lung injury.

Authors:  Brian M Gilliss; Mark R Looney
Journal:  Transfus Med Rev       Date:  2011-01

Review 5.  Transfusion-related acute lung injury (TRALI): current clinical and pathophysiologic considerations.

Authors:  Kelly Swanson; Denis M Dwyre; Jessica Krochmal; Thomas J Raife
Journal:  Lung       Date:  2006 May-Jun       Impact factor: 2.584

6.  Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase.

Authors:  C C Silliman; K L Clay; G W Thurman; C A Johnson; D R Ambruso
Journal:  J Lab Clin Med       Date:  1994-11

Review 7.  The role of neutrophils in the pathogenesis of transfusion-related acute lung injury.

Authors:  Yoke Lin Fung; Christopher C Silliman
Journal:  Transfus Med Rev       Date:  2009-10

8.  Compounds biologically similar to platelet activating factor are present in stored blood components.

Authors:  C C Silliman; C A Johnson; K L Clay; G W Thurman; D R Ambruso
Journal:  Lipids       Date:  1993-05       Impact factor: 1.880

9.  Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation.

Authors:  Nilam S Mangalmurti; Zeyu Xiong; Mei Hulver; Mrunalini Ranganathan; Xiang Hong Liu; Timothy Oriss; Meghan Fitzpatrick; Marc Rubin; Darrell Triulzi; Augustine Choi; Janet S Lee
Journal:  Blood       Date:  2008-12-08       Impact factor: 22.113

10.  Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates.

Authors:  Annette Vetlesen; Mohammad Reza Mirlashari; Ciğdem Akalın Akkök; Marguerite R Kelher; Samina Y Khan; Christopher C Silliman; Jens Kjeldsen-Kragh
Journal:  Transfusion       Date:  2012-05-07       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.